Smart Healthcare × Regenerative Medicine × Drug Discovery
— Delivering a Comprehensive Medical Solution
Compal Electronics (Compal; TWSE: 2324) will participate in the 2025 Taiwan Healthcare+ Expo from December 4–7, 2025, held at TaiNEX 1, 4F Precision Medicine Area in Taipei. This year, Compal’s exhibition theme, “Smart Healthcare × Regenerative Medicine × Drug Discovery,” unites seven medical affiliates and Ruifang Hospital under the concept “From Diagnosis to Reconstruction, From Cells to Mind.” The showcase highlights Compal’s cross-domain innovation and comprehensive healthcare ecosystem, covering AI-based diagnosis, cell therapy, and AI-quantum drug discovery.
Strategic Vision: Ruifang Hospital as the Core Engine of Smart Healthcare
Eric Peng, Executive Vice President of Compal, stated, “Smart healthcare, regenerative medicine, and AI quantum computing are Compal’s next growth engines. We are using Ruifang Hospital as a strategic platform to connect the group’s strengths in AI, cloud technology, manufacturing, and medical research, aiming to deliver clinical-driven, differentiated solutions and seize long-term opportunities in the global smart and precision healthcare markets.” Eric Peng emphasized that quality and trust form the core of the medical industry. By combining expertise in electrical engineering, software, AI, biomedical sciences, and regulatory compliance, Compal continues to accumulate clinical achievements and earn trust from the medical community. He also noted that the company may pursue strategic mergers and international collaborations to accelerate the expansion of its smart healthcare business
AI × Quantum Computing × Smart Healthcare — A Cross-Disciplinary Vision
Compal’s three key highlights — Smart Healthcare, Regenerative Medicine, and Quantum-Enhanced Drug Screening — demonstrate the integration of AI, regenerative technologies, and quantum computation.
Together, these innovations span clinical diagnosis, AI-assisted decision-making, rehabilitation tracking, cell regeneration, and drug development. The exhibition integrates seven Compal medical affiliates: Raypal Biomedical, Hipposcreen Neurotech, Aco Healthcare, Shennona, ARCE Therapeutics, Precisely Printed Medical, and River Regeneration and Rejuvenation Biotechnology, showcasing the group’s comprehensive innovation power.
Highlight 1: Smart Healthcare
AI and data-driven healthcare technologies connect diagnosis, treatment, and care to create a patient-centered medical experience.
- Hipposcreen Neurotech: Demonstrates a real-time, non-invasive AI brainwave analysis system for accurate early assessment of depression and dementia risks.
- Aco Healthcare: Introduces an AI-powered handheld ultrasound device with automatic measurement and diagnostic features for multi-scenario clinical use.
- Shennona: Provides AI imaging × intelligent rehabilitation × cloud tracking services, enabling a closed-loop patient care experience from diagnosis to recovery tracking.
Highlight 2: Regenerative Medicine
Focused on cell and tissue repair technologies, Compal presents cutting-edge regenerative medicine and cell therapy innovations.
- Raypal Biomedical: Operates dual GTP cell preparation centers, offering immune and stem cell therapies with high stability and vitality, and extending regenerative medicine into skincare with the Raypal Plasma Rejuvenation Device.
- ARCE Therapeutics: Specializes in next-generation CAR immune cell therapies. Its leading product, ARD103, developed using DashCAR® technology, enables high-quality CAR-T cell manufacturing in 3–5 days and has begun Phase I clinical trials in the U.S. for AML treatment.
- Precisely Printed Medical: Showcases 3D bioceramic printing technology, producing high-precision biomimetic bone implants that enhance healing efficiency and clinical performance.
- River Regeneration and Rejuvenation Biotechnology: Builds a PIC/S GMP-compliant iPSC donor cell bank, establishing the foundation for precision regenerative medicine.
Highlight 3: Drug Screening × Quantum Computing
Centered on AI innovation, Compal leverages NVIDIA AI infrastructure to drive intelligent processes from drug discovery to manufacturing, accelerating new drug development.
- CGA-QX: Using the Compal GPU Annealer technology simulated on the NVIDIA CUDA-Q open-source platform for hybrid quantum-classical computing, Compal’s quantum team enhances computational performance for faster candidate molecule screening.
- Drug Process Optimization: Leveraging NVIDIA NeMo, the bio-computing team optimizes manufacturing processes using large compound databases for rapid formulation of ideal production conditions.
- AI Antibody Design: Employs NVIDIA BioNeMo and NVIDIA Boltz-2 NIM microservice to streamline antibody development and shorten preclinical R&D timelines.
Deepening Smart Healthcare and Expanding Globally
Compal will continue to advance R&D and clinical applications in smart healthcare and regenerative medicine through AI algorithms, cloud platforms, and biomedical material integration — driving the digital transformation of healthcare models. With strong manufacturing and research capabilities, Compal partners with hospitals and international institutions to build a human-centered smart healthcare ecosystem, offering precise and sustainable solutions for aging societies.
Exhibition Information
- Exhibition Name: 2025 Taiwan Healthcare+ Expo
- Date: December 4–7, 2025
- Venue: TaiNEX 1 (Taipei Nangang Exhibition Center, Hall 1)
- Booth: L517a (4F Precision Medicine Zone)
- Theme: Smart Healthcare × Regenerative Medicine × Drug Discovery
- Participants: Compal Electronics, Ruifang Hospital, Raypal Biomedical, Hipposcreen Neurotech, Aco Healthcare, Shennona, ARCE Therapeutics, Precisely Printed Medical, River Regeneration and Rejuvenation Biotechnology.
About Compal and Its Medical Affiliates
Founded in 1984, Compal Electronics has evolved into a global leader in laptops and smart devices, combining professional management and strong R&D capabilities. Recognized as one of Taiwan’s Top 7 Manufacturing Companies (by CommonWealth Magazine) and consistently listed in Forbes Global 2000, Compal continues to innovate across industries including cloud servers, automotive electronics, and smart healthcare. For more information, visit www.compal.com
Raypal Biomedical
Founded in 2016, Raypal Biomedical is composed of an interdisciplinary team of experienced PhD and master’s researchers, integrating cell biology, biomedical processing, and translational medicine expertise to develop clinical-grade regenerative medicine capabilities. The company operates two GTP-certified cell preparation centers, providing high-activity immune cell and stem cell therapies, and offers one-stop regenerative medicine CDMO services covering process development and technology transfer, GTP-grade manufacturing, release testing, and cold-chain logistics. Raypal also extends regenerative medicine into everyday wellness through its “Raypal Plasma Rejuvenation Device.” More information: https://www.raypal-bio.com/
Hipposcreen Neurotech
Established in 2019 as a joint venture between Compal Electronics and Professor Yi-Hung Liu’s research team from the Department of Electrical and Computer Engineering, National Yang Ming Chiao Tung University. Hipposcreen aims to promote mental well-being through brainwave and AI technologies. Its flagship product, the “U-See” System, analyzes 90-second EEG signals using AI models to provide an objective indicator for depression risk. More information: https://www.hipposcreen-nc.com/
Aco Healthcare
Founded in 2019, Aco Healthcare’s team covers R&D, design, manufacturing, marketing, and sales. Focusing on clinical needs, the company continually optimizes workflows and delivers customized solutions. It has obtained ISO 13485, FDA, CE MDR, and TFDA certifications, ensuring the provision of high-quality, safe, and effective products backed by comprehensive after-sales service. More information: https://acohealthcare.com/
Shennona
Established in 2019, Shennona combines ICT industry resources and precision manufacturing expertise to focus on smart healthcare IoT integration services. From system planning and architecture design to project implementation and maintenance consulting, Shennona helps healthcare institutions rapidly deploy smart medical systems, enhancing both operational efficiency and quality of care. More information: https://www.shennonacorp.com/
ARCE Therapeutics
Founded in 2020 by Compal Chairman Ray C. Chen and General Manager Chien-Tsun Kuan, ARCE therapeutics focuses on developing next-generation CAR immune cell therapies. The company builds high-performance, safe, and rapid cell therapy manufacturing platforms to address unmet medical needs. Its lead product, ARD103, is expected to become the first CAR-T cell therapy for treating AML (acute myeloid leukemia). More information: https://www.arcetherapeutics.com/
Precisely Printed Medical
Founded in 2021 by Professor Chih-Kuang Wang’s team from Kaohsiung Medical University and joined the Compal Group in 2024. Currently a six-member R&D team, Precisely Printed Medical specializes in 3D bio ceramic printing technology, using proprietary slurry materials to produce high-precision biomimetic bone implants that enhance bone healing efficiency and clinical outcomes.
River Regeneration and Rejuvenation Biotechnology
Established in 2022, River Regeneration and Rejuvenation Biotechnology’s vision is to lead iPSC-based therapies and pioneer a new era in regenerative medicine. The company is committed to developing induced pluripotent stem cells (iPSCs) into therapeutic products and has established a clinical-grade “super donor” iPSC cell bank compliant with PIC/S GMP standards — bridging the gap between basic research and clinical application. More information: https://www.river-biotech.com/
Media Contact
Jack Wang Vice President & Spokesperson +886-2-8797-8588 Investor@compal.com